0

Peptide Therapeutics Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

  • Published: Jun 2022
  • Pages: 135
  • SKU: IRTNTR73790
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The peptide therapeutics market share is expected to increase to USD 23.36 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 12.52%.

This peptide therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers peptide therapeutics market segmentation by route of administration (parenteral, oral, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The peptide therapeutics market report also offers information on several market vendors, including Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Worg pharma among others.

What will the Peptide Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Peptide Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Peptide Therapeutics Market: Key Drivers, Trends, and Challenges

The increasing prevalence of infectious diseases is notably driving the peptide therapeutics market growth, although factors such as complexities in manufacturing, storage conditions, distribution policies, and high cost may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the peptide therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Peptide Therapeutics Market Driver

One of the key factors driving the global peptide therapeutics industry growth is the increasing prevalence of infectious diseases. The outbreak of infectious disease has increased due to changing lifestyles, which result in reduced immunity. The pattern of infection incidence has also been changing with the evolution of drug-resistant pathogens. HIV/AIDS is a leading cause of death in many countries, however, it has decreased in many countries since 2010. For instance, the prevalence of meningococcal disease, which is caused by the bacterium Neisseria, meningitides, was decreased, owing to the meningococcal vaccines, which were licensed and made available in August 2020 in the US. According to the CDC data, of 2021, annually, almost 4,100 cases and 500 deaths occur due to meningococcal disease in the US. Thus, a rise in the incidence and prevalence of infectious diseases due to climate change is expected to drive market growth during the forecast period.

Key Peptide Therapeutics Market Trend

Collaboration for research and development is one of the key peptide therapeutics market trends that is expected to impact the industry positively in the forecast period. Companies are entering into strategic alliances to overcome technological and research challenges. For instance, AstraZeneca entered into a collaboration agreement with Bicycle Therapeutics for the development of novel peptide-based therapies using Bicycles, which is Bicycle Therapeutics novel peptide technology for the treatment of respiratory, cardiovascular, and various metabolic disorders. AstraZeneca agreed to pay USD 1 billion to Bicycle Therapeutics. The pharmaceutical companies such as Novo Nordisk, Zealand Pharma, and Zydus Cadila sponsor various research programs with the Peptide Therapeutics Foundation, a not-for-profit organization focusing on the development of peptides for the treatment of various indications, which will further support the market growth in the coming years.

Key Peptide Therapeutics Market Challenge

One of the key challenges to the global peptide therapeutics industry growth is the complexities in manufacturing, storage conditions, distribution policies, and high cost. The manufacturing process of proteins is very complex and time-consuming, as it involves fermentation, clarification, separation, and purification. The purification process is lengthy, and the risk of contamination is high as the drug is produced in a biological medium. All through the process, proper temperature, pressure, and pH should be maintained. For instance, Eprex, a biosimilar, was found to be structurally unidentical to Amgen EPOGEN as small differences were found in the hydrodynamic structure and the degree of alfa helicity, which affected the stability of the product. In addition, these processes require large investments in biotechnology and sterile production facilities. Insulin treatment also suffers from poor storage and distribution policies. Inadequate distribution policies and lack of a centralized supply chain lead to intra-country variability in pricing. Such factors may impede the market growth in the forecast period.

This peptide therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global peptide therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the peptide therapeutics market during the forecast period.

Who are the Major Peptide Therapeutics Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Almac Group Ltd.
  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bachem AG
  • Bristol Myers Squibb Co.
  • Corden Pharma International GmbH
  • Eli Lilly and Co.
  • Ever Pharma
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Lonza Group Ltd.
  • Novartis AG
  • Novo Nordisk AS
  • PeptiDream Inc.
  • Pfizer Inc.
  • PolyPeptide Group
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Worg pharma

 

This statistical study of the peptide therapeutics market encompasses successful business strategies deployed by the key vendors. The peptide therapeutics market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

  • Amgen Inc. - The unified segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics. 
  • Amgen Inc. - The company offers Therapeutic proteins which are extensively used for the treatment of cancer, HIV, and other diseases. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The peptide therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Peptide Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the peptide therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Peptide Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

39% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for peptide therapeutics in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The significant increase in the sales of peptide therapeutics and the rising number of biosimilars will facilitate the peptide therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 pandemic spread widely across North America, especially in the US, in 2020. However, in Q1 2021, the initiation of vaccination programs led to the resumption of business operations, including the supply chain of peptide therapeutics. The regional peptide therapeutics market witnessed positive growth in 2021 due to the increase in the demand for peptide therapeutics to mitigate the threat of COVID-19. Due to this, the regional peptide therapeutics market will grow during the forecast period

What are the Revenue-generating Route of Administration Segments in the Peptide Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The peptide therapeutics market share growth by the parenteral segment will be significant during the forecast period. Most of the major peptide drugs that are currently approved in the market are administered through the parenteral route. The popularity of parenteral RoA for peptide therapeutics is largely due to the rapid absorption of drugs and, thereby, the avoidance of drug loss through first-pass metabolism. Such factors will drive the segment growth in the coming years.

This report provides an accurate prediction of the contribution of all the segments to the growth of the peptide therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Peptide Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 12.52%

Market growth 2022-2026

$ 23.36 billion

Market structure

Fragmented

YoY growth (%)

8.8

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Worg pharma

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Peptide Therapeutics Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive peptide therapeutics market growth during the next five years
  • Precise estimation of the peptide therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the peptide therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of peptide therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Route of Administration

    • 5.1 Market segments
      • Exhibit 24: Chart on Route of Administration - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Route of Administration - Market share 2021-2026 (%)
    • 5.2 Comparison by Route of Administration
      • Exhibit 26: Chart on Comparison by Route of Administration
      • Exhibit 27: Data Table on Comparison by Route of Administration
    • 5.3 Parenteral - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Parenteral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Parenteral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Parenteral - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Parenteral - Year-over-year growth 2021-2026 (%)
    • 5.4 Oral - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Oral - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Oral - Year-over-year growth 2021-2026 (%)
    • 5.5 Others - Market size and forecast 2021-2026
      • Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
      • Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)
    • 5.6 Market opportunity by Route of Administration
      • Exhibit 40: Market opportunity by Route of Administration ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 42: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 44: Chart on Geographic comparison
      • Exhibit 45: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 China - Market size and forecast 2021-2026
      • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.10 UK - Market size and forecast 2021-2026
      • Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.11 Canada - Market size and forecast 2021-2026
      • Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 82: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 83: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 85: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 86: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 87: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 88: Matrix on vendor position and classification
            • 10.3 Amgen Inc.
              • Exhibit 89: Amgen Inc. - Overview
              • Exhibit 90: Amgen Inc. - Product / Service
              • Exhibit 91: Amgen Inc. - Key offerings
            • 10.4 AstraZeneca Plc
              • Exhibit 92: AstraZeneca Plc - Overview
              • Exhibit 93: AstraZeneca Plc - Product / Service
              • Exhibit 94: AstraZeneca Plc - Key news
              • Exhibit 95: AstraZeneca Plc - Key offerings
            • 10.5 Eli Lilly and Co.
              • Exhibit 96: Eli Lilly and Co. - Overview
              • Exhibit 97: Eli Lilly and Co. - Product / Service
              • Exhibit 98: Eli Lilly and Co. - Key offerings
            • 10.6 Ever Pharma
              • Exhibit 99: Ever Pharma - Overview
              • Exhibit 100: Ever Pharma - Product / Service
              • Exhibit 101: Ever Pharma - Key offerings
            • 10.7 GlaxoSmithKline Plc
              • Exhibit 102: GlaxoSmithKline Plc - Overview
              • Exhibit 103: GlaxoSmithKline Plc - Business segments
              • Exhibit 104: GlaxoSmithKline Plc - Key news
              • Exhibit 105: GlaxoSmithKline Plc - Key offerings
              • Exhibit 106: GlaxoSmithKline Plc - Segment focus
            • 10.8 Novo Nordisk AS
              • Exhibit 107: Novo Nordisk AS - Overview
              • Exhibit 108: Novo Nordisk AS - Business segments
              • Exhibit 109: Novo Nordisk AS - Key offerings
              • Exhibit 110: Novo Nordisk AS - Segment focus
            • 10.9 Pfizer Inc.
              • Exhibit 111: Pfizer Inc. - Overview
              • Exhibit 112: Pfizer Inc. - Product / Service
              • Exhibit 113: Pfizer Inc. - Key news
              • Exhibit 114: Pfizer Inc. - Key offerings
            • 10.10 Sanofi
              • Exhibit 115: Sanofi - Overview
              • Exhibit 116: Sanofi - Business segments
              • Exhibit 117: Sanofi - Key news
              • Exhibit 118: Sanofi - Key offerings
              • Exhibit 119: Sanofi - Segment focus
            • 10.11 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 120: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 121: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 122: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 123: Takeda Pharmaceutical Co. Ltd. - Key offerings
            • 10.12 Teva Pharmaceutical Industries Ltd.
              • Exhibit 124: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 125: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 128: Teva Pharmaceutical Industries Ltd. - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 129: Inclusions checklist
                • Exhibit 130: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 131: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 132: Research methodology
                • Exhibit 133: Validation techniques employed for market sizing
                • Exhibit 134: Information sources
              • 11.5 List of abbreviations
                • Exhibit 135: List of abbreviations
              • health: Includes veterinary drugs (excluded from the scope of the report)

                Research Framework

                Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

                TechnavioINFORMATION SOURCES

                Primary sources

                • Manufacturers and suppliers
                • Channel partners
                • Industry experts
                • Strategic decision makers

                Secondary sources

                • Industry journals and periodicals
                • Government data
                • Financial reports of key industry players
                • Historical data
                • Press releases
                Technavio

                TechnavioDATA ANALYSIS

                Data Synthesis

                • Collation of data
                • Estimation of key figures
                • Analysis of derived insights

                Data Validation

                • Triangulation with data models
                • Reference against proprietary databases
                • Corroboration with industry experts
                Technavio

                TechnavioREPORT WRITING

                Qualitative

                • Market drivers
                • Market challenges
                • Market trends
                • Five forces analysis

                Quantitative

                • Market size and forecast
                • Market segmentation
                • Geographical insights
                • Competitive landscape
                Interested in this report?
                Get your FREE sample now!
                The peptide therapeutics market market growth will increase by $$ 23.36 billion during 2023-2026.
                The peptide therapeutics market market is expected to grow at a CAGR of 12.52% during 2023-2026.
                Technavio has segmented the peptide therapeutics market market by other 1 (Parenteral, Oral, and Others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
                Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Worg pharma are a few of the key vendors in the peptide therapeutics market market.
                North America will register the highest growth rate of 39% among the other regions. Therefore, the peptide therapeutics market market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
                The key factors driving the peptide therapeutics market market growth are:
                • Increasing prevalence of infectious diseases
                • Collaborations for research and development
                The peptide therapeutics market market vendors should focus on grabbing business opportunities from the parenteral segment as it accounted for the largest market share in the base year.
                Safe and Secure SSL Encrypted
                Technavio

                Single User:

                2500 USD

                Technavio Get the report (PDF) sent to your email within minutes.

                Subscribe & Save

                Get lifetime access to our
                Technavio Insights

                Want to customize this report?

                This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

                We offer $1000 worth of FREE customization at the time of purchase
                Technavio
                Enquire Before Buying
                1. Home
                2. Health Care
                3. Published Report
                17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>